Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

PGTI Reports 2019 First Quarter Results

Published

on

Reading Time: 9 minutes

First Quarter Sales Growth of $33 Million Driven by Inclusion of
Western Window Systems and Growth in Legacy New Construction Channel

VENICE, Fla.–(BUSINESS WIRE)–PGT Innovations, Inc. (NYSE: PGTI), a national leader in premium windows
and doors, including impact-resistant products and products designed to
unify indoor/outdoor living spaces, today announced financial results
for its first quarter ended March 30, 2019.

Financial Highlights for First Quarter 2019 versus First Quarter 2018

  • Net sales for the first quarter increased 24 percent, to $174 million,
    including $32 million from Western Window Systems
  • Gross profit grew 37 percent, to $61.3 million
  • Net income for the quarter grew 13 percent, to $8.3 million
  • Net income per diluted share was flat at $0.14, and adjusted net
    income per diluted share of $0.16, decreased $0.03 from the prior
    year; both affected by the higher number of shares outstanding,
    resulting from the 2018 equity offering
  • Adjusted EBITDA grew 30 percent, to $28.3 million

In the first quarter, PGT Innovations’ significant growth in sales and
EBITDA was driven by the inclusion of Western Window Systems and the
strength in our new construction channel. In our legacy markets, our
corporate builder program grew significantly versus the prior year
quarter as adoption of our impact products continues to accelerate,”
stated Jeff Jackson, President and Chief Executive Officer of PGT
Innovations.

First quarter sales for Western Window Systems grew versus the
prior-year quarter as its penetration continued to increase in the
indoor/outdoor living market. Integration continues to remain on track,
as expected cost synergies began to be realized in the first quarter and
meaningful progress was achieved in building the infrastructure to begin
selling Western products in our legacy markets,” added Jackson.

Despite the slight decline in the repair and remodel market overlapping
significant growth in the prior year period, we were able to deliver
solid results in the first quarter of 2019, including the growth of
Western Window Systems’ sales and EBITDA compared to its pre-acquisition
prior year period. As we enter hurricane season, we are reaffirming full
year guidance for 2019,” stated Sherri Baker, Senior Vice President and
Chief Financial Officer of PGT Innovations. “Our balance sheet remained
strong at the end of the first quarter, with cash of $45 million and a
net debt-to-adjusted EBITDA ratio, adjusted for the Western Window
Systems acquisition, of 2.2 times,” concluded Baker.

Conference Call

PGT Innovations will host a conference call on Thursday, May 2, 2019, at
10:30 a.m. The conference call will be available at the same time
through the Investor Relations section of the PGT Innovations, Inc.
website, http://ir.pgtinnovations.com/events.cfm.

To participate in the teleconference, kindly dial into the call a few
minutes before the start time: 888-205-6786 (U.S. and Canada) and
786-789-4840 (U.S.). The conference ID is 987008. Please note that these
are new dial-in phone numbers. A replay of the call will be available
within approximately two hours after the scheduled end of the call on
May 2, 2019, through 1:30 p.m. on May 9, 2019. To access the replay,
dial 888-203-1112 (U.S. and Canada) and 719-457-0820 (U.S.) and refer to
pass code 2132984.

You may also join the conference online by using the following link: https://services.choruscall.com/links/pgti190502D1RN8jkQ.html.

The webcast will also be available through the Investors section of the
PGT Innovations, Inc. website: http://ir.pgtinnovations.com/events.cfm.

About PGT Innovations, Inc.

PGT Innovations manufactures and supplies premium windows and doors. Its
highly-engineered and technically-advanced products can withstand some
of the toughest weather conditions on earth and unify indoor/outdoor
living spaces.

PGT Innovations creates value through deep customer relationships,
understanding the unstated needs of the markets it serves and a drive to
develop category-defining products. PGT Innovations is also the nation’s
largest manufacturer of impact-resistant windows and doors, holds the
leadership position in its primary markets, and is part of the S&P
SmallCap 400 Index.

The PGT Innovations’ family of brands include CGI®, PGT® Custom Windows
& Doors, WinDoor®, Western Window Systems®, CGI Commercial® and
Eze-Breeze®. The Company’s brands, in their respective markets, are a
preferred choice of architects, builders, and homeowners throughout
North America and the Caribbean. The Company’s high-quality products are
available in custom and standard sizes with multiple dimensions that
allow for greater design possibilities in residential, multi-family, and
commercial projects. For additional information, visit www.pgtinnovations.com.

Forward-Looking Statements

Statements in this press release regarding our business that are not
historical facts are “forward-looking statements” that involve risks and
uncertainties which could cause actual results to differ materially from
those contained in the forward-looking statements. Such forward-looking
statements generally can be identified by the use of forward-looking
terminology, such as “may,” “expect,” “expectations,” “outlook,”
“forecast,” “guidance,” “intend,” “believe,” “could,” “project,”
“estimate,” “anticipate,” “should,” “plan” and similar terminology.
These risks and uncertainties include factors such as:

  • adverse changes in new home starts and home repair and remodeling
    trends, especially in the state of Florida, where the substantial
    portion of our sales are currently generated, and in the western
    United States, where the substantial portion of the sales of Western
    Window Systems’ operations are generated, and in the U.S. generally;
  • macroeconomic conditions in Florida, where the substantial portion of
    our sales are generated, and in California, Texas, Arizona, Nevada,
    Colorado, Oregon, Washington and Hawaii, where the substantial portion
    of the sales of Western Window Systems are currently generated, and in
    the U.S. generally;
  • our level of indebtedness, which increased in connection with our
    acquisition of Western Window Systems;
  • the effects of increased expenses or unanticipated liabilities
    incurred as a result of, or due to activities related to, the Western
    Window Systems acquisition;
  • the risk that the anticipated cost savings, synergies, revenue
    enhancement strategies and other benefits expected from the Western
    Window Systems acquisition may not be fully realized or may take
    longer to realize than expected or that our actual integration costs
    may exceed our estimates;
  • raw material prices, especially for aluminum, glass and vinyl,
    including, price increases due to the implementation of tariffs and
    other trade-related restrictions;
  • our dependence on a limited number of suppliers for certain of our key
    materials;
  • sales fluctuations to and changes in our relationships with key
    customers;
  • increases in bad debt owed to us by our customers in the event of a
    downturn in the home repair and remodeling or new home construction
    channels in our core markets and our inability to collect such debt;
  • in addition to the Western Window Systems acquisition, our ability to
    successfully integrate businesses we may acquire, or that any business
    we acquire may not perform as we expected at the time we acquired it;
  • increases in transportation costs, including due to increases in fuel
    prices;
  • our dependence on our impact-resistant product lines and contemporary
    indoor/outdoor window and door systems, and on consumer preferences
    for those types and styles of products;
  • product liability and warranty claims brought against us;
  • federal, state and local laws and regulations, including unfavorable
    changes in local building codes and environmental and energy code
    regulations;
  • our dependence on our limited number of geographically concentrated
    manufacturing facilities;
  • risks associated with our information technology systems, including
    cybersecurity-related risks, such as unauthorized intrusions into our
    systems by “hackers” and theft of data and information from our
    systems, and the risks that our information technology systems do not
    function as intended or experience temporary or long-term failures to
    perform as intended; and
  • the risks and uncertainties discussed under Part I, Item 1A, “Risk
    Factors” in the Company’s Annual Report on Form 10-K for the year
    ended December 29, 2018.

Statements in this press release that are forward-looking statements
include, without limitation, our expectations regarding: (1) demand for
our products going forward, including the demand for our
impact-resistant products and the products of Western Window Systems;
(2) our ability to gain market share in 2019 and beyond; (3) the
Company’s ability to continue to grow its sales and earnings in 2019 and
going forward; (4) our ability to position ourselves as a national
leader in the premium window and door market, and our performance in
that market; (5) our integration of Western Windows Systems and
achievement of synergies related thereto; and (6) our financial and
operational performance for our 2019 fiscal year, including our 2019
fiscal year outlook reaffirmed and set forth in this press release. You
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Except as required by law, the Company undertakes no obligation to
update these forward-looking statements to reflect subsequent events or
circumstances from the date of this press release.

Use of Non-GAAP Financial Measures

This press release and the financial schedules include financial
measures and terms not calculated in accordance with U.S. generally
accepted accounting principles (GAAP). We believe that presentation of
non-GAAP measures such as adjusted net income, adjusted net income per
share, and adjusted EBITDA provides investors and analysts with an
alternative method for assessing our operating results in a manner that
enables investors and analysts to more thoroughly evaluate our current
performance compared to past performance. We also believe these non-GAAP
measures provide investors with a better baseline for assessing our
future earnings potential. The non-GAAP measures included in this press
release are provided to give investors access to types of measures that
we use in analyzing our results.

Adjusted net income consists of GAAP net income adjusted for the items
included in the accompanying reconciliation. Adjusted net income per
share consists of GAAP net income per share adjusted for the items
included in the accompanying reconciliation. We believe these measures
enable investors and analysts to more thoroughly evaluate our current
performance as compared to the past performance and provide a better
baseline for assessing the Company’s future earnings potential. However,
these measures do not provide a complete picture of our operations.

Adjusted EBITDA consists of net income, adjusted for the items included
in the accompanying reconciliation. We believe that adjusted EBITDA
provides useful information to investors and analysts about the
Company’s performance because they eliminate the effects of
period-to-period changes in taxes, costs associated with capital
investments and interest expense. Adjusted EBITDA does not give effect
to the cash the Company must use to service its debt or pay its income
taxes and thus does not reflect the actual funds generated from
operations or available for capital investments.

Our calculation of adjusted net income, adjusted net income per share,
and adjusted EBITDA are not necessarily comparable to calculations
performed by other companies and reported as similarly titled measures.
These non-GAAP measures should be considered in addition to results
prepared in accordance with GAAP but should not be considered a
substitute for or superior to GAAP measures. Schedules that reconcile
adjusted net income, adjusted net income per share, and adjusted EBITDA
to GAAP net income are included in the financial schedules accompanying
this release.

Adjusted EBITDA as used in the calculation of the net debt-to-Adjusted
EBITDA ratio, consists of our adjusted EBITDA as described above, but
for the trailing twelve-month period, adjusted pursuant to the covenants
contained in the 2016 Credit Agreement due 2022 for the acquisition of
Western Window Systems.

PGT INNOVATIONS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited – in thousands, except per share amounts)
 
Three Months Ended
March 30, March 31,
2019 2018
 
Net sales $ 173,737 $ 140,253
Cost of sales 112,467 95,480
Gross profit 61,270 44,773
Selling, general and administrative expenses 44,014 28,657
Income from operations 17,256 16,116
Interest expense, net 6,714 4,043
Debt extinguishment costs 3,079
Income before income taxes 10,542 8,994
Income tax expense 2,285 1,654
Net income $ 8,257 $ 7,340
 
Basic net income per common share $ 0.14 $ 0.15
 
Diluted net income per common share $ 0.14 $ 0.14
 
Weighted average common shares outstanding:
Basic 58,134 49,858
 
Diluted 59,220 51,998
PGT INNOVATIONS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited – in thousands)
     
 
March 30, December 29,
2019 2018
ASSETS
Current assets:
Cash and cash equivalents $ 44,936 $ 52,650
Accounts receivable, net 76,035 80,717
Inventories 47,962 44,666
Contract assets, net 9,375 6,757
Prepaid expenses and other current assets 15,812 10,771
Total current assets 194,120 195,561
 
Property, plant and equipment, net 120,238 115,707
Operating lease right-of-use asset, net 29,568
Intangible assets, net 267,803 271,818
Goodwill 277,827 277,827
Other assets, net 1,192 1,240
Total assets $ 890,748 $ 862,153
 
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses $ 56,963 $ 68,557
Current portion of long-term debt 87 163
Current portion of operating lease liability 7,016
Total current liabilities 64,066 68,720
 
Long-term debt, less current portion 367,041 366,614
Operating lease liability, less current portion 25,510
Deferred income taxes, net 23,144 22,758
Other liabilities 15,139 18,517
Total liabilities 494,900 476,609
 
Total shareholders’ equity 395,848 385,544
Total liabilities and shareholders’ equity $ 890,748 $ 862,153
PGT INNOVATIONS, INC.
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO THEIR GAAP
EQUIVALENTS
(unaudited – in thousands, except per share amounts and
percentages)
   
Three Months Ended
March 30, March 31,
2019 2018
Reconciliation to Adjusted Net Income and
Adjusted Net Income per share (1):
Net income $ 8,257 $ 7,340
Reconciling items:
Product line transition costs (2) 641
Acquisition costs (3) 650
Debt extinguishment costs (4) 3,079
Facility and equipment relocation costs (5) 435
Tax effect of reconciling items (332) (906)
Adjusted net income $ 9,216 $ 9,948
Weighted-average diluted shares 59,220 51,998
Adjusted net income per share – diluted $0.16 $0.19
Reconciliation to Adjusted EBITDA (1):
Depreciation and amortization expense $ 8,512 $ 4,620
Interest expense, net 6,714 4,043
Income tax expense 2,285 1,654
Reversal of tax effect of reconciling items for
adjusted net income above 332 906
Stock-based compensation expense 1,198 514
Adjusted EBITDA $ 28,257 $ 21,685
Adjusted EBITDA as percentage of net sales 16.3% 15.5%

Net debt-to-Adjusted EBITDA ratio as adjusted for Western Window
Systems (6)

2.2x

(1) The Company’s non-GAAP financial measures were explained in its
Form 8-K filed May 2, 2019.
 
(2) Represents costs relating to product line transitions,
classified within cost of sales for the three months ended March 30,
2019.
 
(3) Represents costs relating to the Western Window Systems
acquisition, classified within selling, general and administrative
expenses for the three months ended March 30, 2019.
 

(4) Represents debt extinguishment costs for the three months
ended March 31, 2018, relating to the Company’s March 16, 2018
refinancing and second amendment of the 2016 Credit Agreement due
2022.

 
(5) Represents costs associated with planned relocation of the CGI
Windows & Doors manufacturing operations to its new facility in
Miami, FL, and costs associated with machinery and equipment
relocations within our glass plant operations in Venice, FL as the
result of our planned disposal of certain glass manufacturing assets
to Cardinal Glass Industries. Of the $435 thousand, $416 thousand is
classified within cost of sales during the three months ended March
31, 2018, with the remainder classified within selling, general and
administrative expenses.
 

(6) Calculated in accordance with the covenants pursuant to the
2016 Credit Agreement due 2022 for the acquisition of Western
Window Systems.

Contacts

Investor Relations:
Sherri Baker, 941-480-1600
Senior
Vice President and CFO
[email protected]

Media Relations:
Brent Boydston, 941-480-1600
Senior
Vice President, Corporate Sales and Marketing
[email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Rubicon Organics Reports Q1 2024 Financial Results

Published

on

Continue Reading

SCHWAZZE

Schwazze Announces First Quarter 2024 Financial Results

Published

on

schwazze-announces-first-quarter-2024-financial-results

Schwazze Management to Host Conference Call Today at 5:00 p.m. Eastern Time

DENVER, May 15, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (Cboe CA: SHWZ) (“Schwazze” or the “Company”), today announced financial and operational results for the first quarter ended March 31, 2024.

“We delivered another period of revenue growth in Q1 as we further refined our retail strategy while contending with the prolonged competitive challenges in Colorado and New Mexico,” said Forrest Hoffmaster, Interim CEO of Schwazze. “Throughout the quarter, we continued to sharpen our pricing and promotional efforts while enhancing the in-store experience, widening assortment, improving in-stock position, and advancing our loyalty program to attract and retain new customers. We also strengthened our wholesale business with quarter-over-quarter growth, while surpassing 30% total door penetration across both states.”

“The Colorado market remains highly competitive with more than 680 active recreational licenses, underscoring the importance of delivering an exceptional customer experience and fully integrated retail support program. Although retail pricing has recently stabilized, Colorado sales in Q1 were down 10% year-over-year due to lower volumes. Nonetheless, we significantly outpaced the market as our sales were up 9%, demonstrating the effectiveness of our operating playbook to compete in challenging environments. We expect to continue driving improvements in customer acquisition, retention, and loyalty as we further increase market share in the state.”

“In New Mexico, the proliferation of new licenses continued to outpace state cannabis sales as store count in Q1 increased 31% year-over-year while the market grew only 13%. In addition to pricing and promotional efforts, we’ve focused on driving traffic into our stores by expanding assortment with high quality flower and delivering an elevated customer experience. The New Mexico regulatory body has also increased its license enforcement efforts in recent months, contributing to more than 70 store closures and a 33% sequential decrease in net new store openings in the first quarter. We will continue to support the New Mexico Cannabis Control Division as it develops its regulatory framework.”

“Over the past four years we have rapidly scaled our footprint through 13 acquisitions, building a leading retail presence in both Colorado and New Mexico. We are beginning to see positive momentum from our pricing and promotional strategy and will remain focused on driving operating efficiencies while further optimizing our assets as we consolidate cultivation facilities and eliminate underperforming stores that do not meet our high-margin thresholds. We believe these initiatives, coupled with our operating playbook and strict cost controls, will enable us to return to stronger levels of profitability moving forward.”

First Quarter 2024 Financial Summary

$ in Thousands USD

Q1 2024

Q4 2023

Q1 2023

Total Revenue

$41,601

$43,325

$40,001

Gross Profit

$17,934

$7,034[1]

$21,849

Operating Expenses

$20,643

$23,276

$16,199

Income (Loss) from Operations

$(2,709)

$(16,242)

$5,650

Adjusted EBITDA[2]

$7,341

$10,953

$14,525

Operating Cash Flow

$(3,700)

$3,452

$(880)

Recent Highlights

  • Announced the grand opening of a medical and recreational dispensary in March under the Everest Apothecary banner in Las Cruces, New Mexico, increasing the Company’s retail footprint to 34 stores across the state.
  • Increased wholesale penetration in the first quarter to more than 30% of total doors in Colorado and New Mexico.
  • Lowell Herb Co. pre-roll sales increased more than 3x quarter-over-quarter in Colorado, where it continues to be the #1 pre-roll in the state.
  • Wana gummy sales up more than 2x quarter-over-quarter in New Mexico.

First Quarter 2024 Financial Results

Total revenue in the first quarter of 2024 increased 4% to $41.6 million compared to $40.0 million for the same quarter last year. The increase was primarily due to growth from new stores compared to the prior year period, partially offset by continued pricing pressure and the proliferation of new licenses in New Mexico.

Gross profit for the first quarter of 2024 was $17.9 million or 43.1% of total revenue, compared to $21.8 million or 54.6% of total revenue for the same quarter last year. The decrease in gross margin was primarily driven by the aforementioned pricing pressure in New Mexico, as well as higher medical sales mix in Colorado.

____________________________

1 Q4 2023 Gross Profit includes one-time, non-cash inventory adjustments of approximately $13.1 million comprised of $3.1 million of product consolidation, obsolescence, and shrinkage expenses, $4.3 million of net realizable value adjustments, and $5.8 million of fair value adjustments on acquired inventory in New Mexico in 2023. 
2  Adjusted EBITDA is a non-GAAP measure as defined by the SEC, and represents earnings before interest, taxes, depreciation, and amortization, adjusted for other income, non-cash share-based compensation, one-time transaction related expenses, or other non-operating costs. The Company uses Adjusted EBITDA as it believes it better explains the results of its core business. See “ADJUSTED EBITDA RECONCILIATION (NON-GAAP)” section herein for an explanation and reconciliations of non-GAAP measure used throughout this release.

Operating expenses for the first quarter of 2024 were $20.6 million compared to $16.2 million for the same quarter last year. The year-ago period benefitted from a payroll tax credit of $3.9M. The remaining increase was primarily driven by personnel expenses and four-wall SG&A costs associated with 21 additional stores in Colorado and New Mexico that are still ramping.

Loss from operations for the first quarter of 2024 was $2.7 million compared to income from operations of $5.6 million in the same quarter last year. Net loss was $16.1 million for the first quarter of 2024 compared to net income of $1.7 million for the same quarter last year.

Adjusted EBITDA for the first quarter of 2024 was $7.3 million compared to $14.5 million for the same quarter last year. The decrease in Adjusted EBITDA was primarily driven by lower gross margin and higher operating expenses associated with the 21 additional stores that are still ramping.

As of March 31, 2024, cash and cash equivalents were $13.2 million compared to $19.2 million on December 31, 2023. Total debt as of March 31, 2024, was $159.7 million compared to $156.8 million on December 31, 2023.

Conference Call

The Company will conduct a conference call today, May 15, 2024, at 5:00 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2024.

Schwazze management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing [email protected].

Date: Wednesday, May 15, 2024
Time: 5:00 p.m. Eastern time
Toll-free dial-in: (888) 664-6383
International dial-in: (416) 764-8650
Conference ID: 84167910
Webcast: SHWZ Q1 2024 Earnings Call

The conference call will also be broadcast live and available for replay on the investor relations section of the Company’s website at https://ir.schwazze.com.

Toll-free replay number: (888) 390-0541
International replay number: (416) 764-8677
Replay ID: 167910

If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.

About Schwazze

Schwazze (OTCQX: SHWZ) (Cboe CA: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to explore taking its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include financial outlooks; any projections of net sales, earnings, or other financial items; any statements of the strategies, plans and objectives of our management team for future operations; expectations in connection with the Company’s previously announced business plans; any statements regarding future economic conditions or performance; and statements regarding the intent, belief or current expectations of our management team. Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. We have based our forward-looking statements on management’s current expectations and assumptions about future events and trends affecting our business and industry. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Therefore, forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected]

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
For the Periods Ended March 31, 2024 and December 31, 2023
Expressed in U.S. Dollars

 March 31,

December 31, 

2024

2023

 

ASSETS

 

Current Assets

Cash & Cash Equivalents

$

13,151,317

$

19,248,932

Accounts Receivable, net of Allowance for Doubtful Accounts

3,356,032

4,261,159

Inventory

26,382,184

25,787,793

Marketable Securities, net of Unrealized Loss of $347,516 and Loss of $1,816, respectively

108,583

456,099

Prepaid Expenses & Other Current Assets

3,502,310

3,914,064

Total Current Assets

46,500,426

53,668,047

Non-Current Assets

Fixed Assets, net Accumulated Depreciation of $10,061,700 and $8,741,782, respectively

31,326,000

31,113,630

Investments

2,000,000

2,000,000

Investments Held for Sale

202,111

Goodwill

67,492,705

67,499,199

Intangible Assets, net Accumulated Amortization of $36,483,160 and $32,706,765, respectively

162,391,482

166,167,877

Other Non-Current Assets

1,328,187

1,263,837

Operating Lease Right of Use Assets

34,575,832

34,233,142

Deferred Tax Assets, net

992,144

1,996,489

Total Non-Current Assets

300,106,350

304,476,285

Total Assets

$

346,606,776

$

358,144,332

 

LIABILITIES & STOCKHOLDERS’ EQUITY

 

Current Liabilities

Accounts Payable

$

9,443,233

$

13,341,561

Accrued Expenses

8,106,618

7,774,691

Derivative Liabilities

1,319,845

638,020

Lease Liabilities – Current

5,186,316

4,922,724

Current Portion of Long Term Debt

29,579,713

3,547,011

Income Taxes Payable

28,235,039

25,232,782

Total Current Liabilities

81,870,764

55,456,789

Non-Current Liabilities

Long Term Debt, net of Debt Discount & Issuance Costs

130,120,753

153,262,203

Lease Liabilities – Non-Current

30,735,072

30,133,452

Total Non-Current Liabilities

160,855,825

183,395,655

Total Liabilities

$

242,726,589

$

238,852,444

Stockholders’ Equity

Preferred Stock, $0.001 Par Value. 10,000,000 Shares Authorized; 82,185 Shares Issued and

82,185 Outstanding as of March 31, 2024 and 85,534 Shares Issued and 85,534 Outstanding as of

December 31, 2023.

82

86

Common Stock, $0.001 Par Value. 250,000,000 Shares Authorized; 79,168,539 Shares Issued

and 78,248,389 Shares Outstanding as of March 31, 2024 and 74,888,392 Shares Issued

and 73,968,242 Shares Outstanding as of December 31, 2023.

79,169

74,888

Additional Paid-In Capital

202,677,665

202,040,968

Accumulated Deficit

(96,843,602)

(80,790,927)

Common Stock Held in Treasury, at Cost, 920,150 Shares Held as of March 31, 2024 and

920,150 Shares Held as of December 31, 2023.

(2,033,127)

(2,033,127)

Total Stockholders’ Equity

103,880,187

119,291,888

Total Liabilities & Stockholders’ Equity

$

346,606,776

$

358,144,332

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME AND (LOSS)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

(Unaudited)

(Unaudited)

Operating Revenues

Retail

$

37,633,252

$

35,820,111

Wholesale

3,898,320

4,058,925

Other

69,421

121,900

Total Revenue

41,600,993

40,000,936

Total Cost of Goods & Services

23,667,319

18,152,163

Gross Profit

17,933,674

21,848,773

Operating Expenses

Selling, General and Administrative Expenses

11,835,818

10,100,934

Professional Services

1,671,881

1,187,364

Salaries

6,880,988

4,695,971

Stock Based Compensation

253,916

214,544

Total Operating Expenses

20,642,603

16,198,813

Income from Operations

(2,708,929)

5,649,960

Other Income (Expense)

Interest Expense, net

(8,307,369)

(7,745,854)

Unrealized Gain (Loss) on Derivative Liabilities

(681,825)

8,501,685

Other Loss

10,500

Loss on Investment

(33,382)

Unrealized Gain on Investment

(347,516)

1,816

Total Other Income (Expense)

(9,359,592)

757,647

Pre-Tax Net Income (Loss)

(12,068,521)

6,407,607

Provision for Income Taxes

3,984,154

4,662,178

Net Income (Loss)

$

(16,052,675)

$

1,745,429

Less: Accumulated Preferred Stock Dividends for the Period

(2,155,259)

(2,029,394)

Net Income (Loss) Attributable to Common Stockholders

$

(18,207,934)

$

(283,965)

Earnings (Loss) per Share Attributable to Common Stockholders

Basic Earnings (Loss) per Share

$

(0.24)

$

(0.01)

Diluted Earnings (Loss) per Share

$

(0.24)

$

(0.06)

Weighted Average Number of Shares Outstanding – Basic

76,006,932

55,835,501

Weighted Average Number of Shares Outstanding – Diluted

76,006,932

101,608,278

Comprehensive Income (Loss)

$

(16,052,675)

$

1,745,429

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

(Unaudited)

(Unaudited)

Cash Flows from Operating Activities:

Net Income (Loss) for the Period

$

(16,052,675)

$

1,745,429

Adjustments to Reconcile Net Income (Loss) to Cash for Operating Activities

Depreciation & Amortization

5,096,314

6,151,395

Non-Cash Interest Expense

1,031,431

991,184

Non-Cash Lease Expense

2,871,226

2,251,459

Deferred Taxes

1,004,345

(637,225)

Loss on Investment

202,111

Change in Derivative Liabilities

681,825

(8,501,685)

Amortization of Debt Issuance Costs

421,512

421,513

Amortization of Debt Discount

2,303,246

1,999,933

(Gain) Loss on Investments, net

347,516

(1,816)

Stock Based Compensation

640,974

214,544

Changes in Operating Assets & Liabilities (net of Acquired Amounts):

Accounts Receivable

905,127

(118,181)

Inventory

(587,900)

(3,023,251)

Prepaid Expenses & Other Current Assets

411,754

(3,036,801)

Other Assets

(64,350)

360,674

Change in Operating Lease Liabilities

(2,348,703)

(1,531,765)

Accounts Payable & Other Liabilities

(3,566,401)

(3,464,671)

Income Taxes Payable

3,002,257

5,299,403

Net Cash Provided by (Used in) Operating Activities

(3,700,390)

(879,861)

Cash Flows from Investing Activities:

Collection of Notes Receivable

10,631

Purchase of Fixed Assets

(1,532,287)

(2,913,394)

Net Cash Provided by (Used in) Investing Activities

(1,532,287)

(2,902,763)

Cash Flows from Financing Activities:

Payment on Notes Payable

(864,938)

Net Cash Provided by (Used in) Financing Activities

(864,938)

Net (Decrease) in Cash & Cash Equivalents

(6,097,615)

(3,782,624)

Cash & Cash Equivalents at Beginning of Period

19,248,932

38,949,253

Cash & Cash Equivalents at End of Period

$

13,151,317

$

35,166,628

Supplemental Disclosure of Cash Flow Information:

Cash Paid for Interest

$

4,515,205

$

6,540,748

MEDICINE MAN TECHNOLOGIES, INC.
ADJUSTED EBITDA RECONCILIATION (NON-GAAP)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

Net Income (Loss)

$

(16,052,675)

$

1,745,429

Interest Expense, net

8,307,369

7,745,854

Provision for Income Taxes

3,984,154

4,662,178

Other (Income) Expense, net of Interest Expense

1,052,223

(8,503,501)

Depreciation & Amortization

5,618,834

6,612,814

Earnings Before Interest, Taxes, Depreciation and

Amortization (EBITDA) (non-GAAP)

$

2,909,905

$

12,262,774

Non-Cash Stock Compensation

253,916

214,544

Deal Related Expenses

637,761

1,195,802

Capital Raise Related Expenses

20,760

35,068

Severance

484,561

118,436

Retention Program Expenses

807,500

280,632

Pre-Operating & Dark Carry Expenses

1,053,837

391,917

One-Time Legal Settlements

417,653

Other Non-Recurring Items

754,751

25,707

Adjusted EBITDA (non-GAAP)

$

7,340,644

$

14,524,880

Revenue

41,600,993

40,000,936

Adjusted EBITDA Percent

17.6 %

36.3 %

View original content:https://www.prnewswire.co.uk/news-releases/schwazze-announces-first-quarter-2024-financial-results-302146858.html

Continue Reading

Cannabis

Polyethylene Films Packaging Market Size to Worth USD 139.98 Bn by 2032

Published

on

Continue Reading
Advertisement

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania